avapritinib
Selected indexed studies
- Avapritinib versus Placebo in Indolent Systemic Mastocytosis. (NEJM Evid, 2023) [PMID:38320129]
- Avapritinib. (, 2012) [PMID:37782739]
- Avapritinib: First Approval. (Drugs, 2020) [PMID:32100250]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Avapritinib versus Placebo in Indolent Systemic Mastocytosis. (2023) pubmed
- Avapritinib. (2012) pubmed
- Avapritinib: First Approval. (2020) pubmed
- Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. (2025) pubmed
- Avapritinib. (2006) pubmed
- PMID:39715309 (2024) pubmed
- Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. (2021) pubmed
- Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. (2021) pubmed
- Avapritinib in the Treatment of Systemic Mastocytosis: an Update. (2021) pubmed
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. (2020) pubmed